Agilent Buys Nucleic Acid Medicines Business from Dowpharma | GenomeWeb
NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it has acquired the nucleic acid medicines business of Dowpharma for an undisclosed sum.
 
The acquisition is concurrent with an expansion of its nucleic acid active pharmaceutical ingredient manufacturing facility in Boulder, Colo. Agilent said that it would add large-scale nucleic acid synthesis, purification, and drying capacity to its capabilities by the end of this year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.